These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 437259)

  • 1. 2-Phenylethylamine and amphetamine in human brain: effects of L-deprenyl in Parkinson's disease [proceedings].
    Reynolds GP; Riederer P; Sandler M
    Biochem Soc Trans; 1979 Feb; 7(1):143-5. PubMed ID: 437259
    [No Abstract]   [Full Text] [Related]  

  • 2. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration.
    Reynolds GP; Riederer P; Sandler M; Jellinger K; Seemann D
    J Neural Transm; 1978; 43(3-4):271-7. PubMed ID: 745019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease.
    Stern GM; Lees AJ; Hardie RJ; Sandler M
    Acta Neurol Scand Suppl; 1983; 95():113-6. PubMed ID: 6428142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pharmacological aspects of (-)-deprenyl treatment in Parkinson's disease.
    Stern GM; Lees AJ; Hardie R; Sandler M
    Mod Probl Pharmacopsychiatry; 1983; 19():215-9. PubMed ID: 6408407
    [No Abstract]   [Full Text] [Related]  

  • 5. MAO-B-Inhibitor selegiline (R-(-)-deprenyl). A new therapeutic concept in the treatment of Parkinson's disease. Proceedings of the international symposium. Berlin, January 23-25, 1987.
    J Neural Transm Suppl; 1987; 25():1-197. PubMed ID: 3123595
    [No Abstract]   [Full Text] [Related]  

  • 6. The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.
    Elsworth JD; Sandler M; Lees AJ; Ward C; Stern GM
    J Neural Transm; 1982; 54(1-2):105-10. PubMed ID: 6809891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The use of L-deprenyl in Parkinson's disease].
    Zhonghua Yi Xue Za Zhi; 1983 Mar; 63(3):147-9. PubMed ID: 6409375
    [No Abstract]   [Full Text] [Related]  

  • 8. Deprenyl for the treatment of early Parkinson's disease.
    N Engl J Med; 1990 May; 322(21):1526-8. PubMed ID: 2110624
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
    Csanda E; Tárczy M
    Acta Neurol Scand Suppl; 1983; 95():117-22. PubMed ID: 6428143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deprenyl as symptomatic therapy in Parkinson's disease.
    Golbe LI
    Clin Neuropharmacol; 1988 Oct; 11(5):387-400. PubMed ID: 3146432
    [No Abstract]   [Full Text] [Related]  

  • 11. Deprenyl and the progression of Parkinson's disease.
    Science; 1990 Jul; 249(4966):303-4. PubMed ID: 2115691
    [No Abstract]   [Full Text] [Related]  

  • 12. Deprenyl in Parkinson's disease.
    Lancet; 1982 Sep; 2(8300):695-6. PubMed ID: 6126632
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.
    Karoum F; Chuang LW; Eisler T; Calne DB; Liebowitz MR; Quitkin FM; Klein DF; Wyatt RJ
    Neurology; 1982 May; 32(5):503-9. PubMed ID: 6803190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.
    Birkmayer W; Knoll J; Riederer P; Youdim MB
    Mod Probl Pharmacopsychiatry; 1983; 19():170-6. PubMed ID: 6408405
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics and metabolism of selegiline.
    Heinonen EH; Myllylä V; Sotaniemi K; Lamintausta R; Salonen JS; Anttila M; Savijärvi M; Kotila M; Rinne UK
    Acta Neurol Scand Suppl; 1989; 126():93-9. PubMed ID: 2515726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-deprenyl in the treatment of Parkinson's disease.
    Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G
    J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
    Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A
    N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of L-Deprenyl on on-off phenomena in Parkinson's disease.
    Brodersen P; Philbert A; Gulliksen G; Stigård A
    Acta Neurol Scand; 1985 Jun; 71(6):494-7. PubMed ID: 3927650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-deprenyl treatment of on-off phenomena in Parkinson's disease.
    Rinne UK; Siirtola T; Sonninen V
    J Neural Transm; 1978; 43(3-4):253-62. PubMed ID: 745018
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.